This spring, the Supreme Court of Canada (SCC) will consider the scope of patentable subject-matter as it relates to “methods ...

Expenses incurred by a generic drug manufacturer in defending Hatch-Waxman patent litigation are deductible as ordinary and necessary business expenses, the U.S. Court of Appeals for the Federal ...

Prometric, a global leader in professional and educational assessment, has achieved a major industry milestone by securing the first U.S. patent for AI-powered item generation technology. The patent—U ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Google has a new policy proposal regarding AI and copyright, but it sounds like Google just wants to rewrite the rules in its ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, ...

The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...